The fate of a thiazolidinedione antidiabetic agent in rat and dog
- 1 January 1996
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 26 (6) , 627-636
- https://doi.org/10.3109/00498259609046738
Abstract
1. The fate of [14C]BRL 49653C, a novel thiazolidinedione antidiabetic agent, has been studied following oral administration to the rat and dog. 2. Clearance was almost exclusively by metabolism, with only small amounts of unchanged BRL 49653 being excreted by either species. 3. Phase I metabolism resulted in ring hydroxylation, N-demethylation and oxidative removal of the pyridinylamino function to yield a phenoxyacetic acid derivative. 4. Sulphation of phase I metabolites occurred in both species, but glucuronidation was only observed in the rat. 5. The parent compound was the major circulating component in both species at early times, but at later times sulphate conjugates of phase 1 metabolites were predominant.Keywords
This publication has 6 references indexed in Scilit:
- Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells.Molecular Pharmacology, 1994
- Disposition and metabolism of the hypoglycemic agent pioglitazone in rats.Drug Metabolism and Disposition, 1994
- Metabolism of a new thiazolidinedione hypoglycemic agent CP-68,722 in rat: Metabolite identification by gas chromatography mass spectrometryXenobiotica, 1991
- Disposition in rats and dogs of ciglitazone, a new antidiabetic agentXenobiotica, 1984
- Rat-plasma metabolites of ciglitazone, a new antidiabetic agentXenobiotica, 1984
- A novel technique for assessment of biliary secretion and enterohepatic circulation in the unrestrained conscious ratXenobiotica, 1981